Skip to main content
. 2023 May 2;100(18):e1900–e1911. doi: 10.1212/WNL.0000000000207138

Figure 1. mRS Scores at 90 Days Stratified by Treatment in Patients With a Tandem Lesion (A) and Without a Tandem Lesion (B).

Figure 1

(A) No significant differences were observed between tenecteplase (pooled analysis of 0.25 and 0.40 mg/kg dosing) and alteplase (acOR 1.48 95% CI 0.44–5.00), adjusting for baseline NIH Stroke Scale, age, time from symptom onset to arterial puncture, and study. (B) No significant differences were observed between tenecteplase (pooled analysis of 0.25 mg/kg and 0.40 mg/kg dosing) and alteplase (acOR 1.49 95% CI 0.85–2.60), adjusting for baseline NIH Stroke Scale, age, time from symptom onset to arterial puncture, and study. acOR = adjusted common odds radio; mRS = modified Rankin scale.